A Decades Progress in the Development of Molecular Imaging Agents Targeting the Growth Hormone Secretagogue Receptor
14 A calculator to assess cardiovascular disease risk in people with type 2 diabetes is available here: Clinical scenarios where empagliflozin or dulaglutide are recommended, but not funded The recently released type 2 diabetes management guidelines developed by the New Zealand Society for the Study of Diabetes (NZSSD), and supported by the Ministry of Health, state that while the Special Authority criteria for empagliflozin and GLP-1 receptor agonists ensure access for those at high risk of cardiovascular and renal disease, the funding restriction is not fully consistent with best practice
Empower generated $311 million in revenue through the first 10 months of 2024, according to an internal sales dashboard obtained by the Houston Chronicle
Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in popularity in recent years
Semaglutide may be a good starting option for individuals beginning GLP-1 treatment, while tirzepatide may be considered when additional appetite control or metabolic support is needed
These are estimates and not guarantees
)
